Abstract
The study of different genes, chromosomes and the spatiotemporal relationship between them is of great significance in the field of biomedicine. CRISPR-Cas9 has become the most widely used gene editing tool due to its excellent targeting ability. In recent years, a series of advanced imaging technologies based on Cas9 have been reported, providing fast and convenient tools for studying the sites location of genome, RNA, and chromatin. At the same time, a variety of CRISPR-Cas9-based imaging systems have been developed, which are widely used in real-time multi-site imaging in vivo. In this review, we summarized the component and mechanism of CRISPR-Cas9 system, overviewed the NIR imaging and the application of NIR fluorophores in the delivery of CRISPR-Cas9, and highlighted advances of the CRISPR-Cas9-based imaging system. In addition, we also discussed the challenges and potential solutions of CRISPR-Cas9-based imaging methods, and looked forward to the development trend of the field.
Keywords: CRISPR-Cas9, NIR imaging, NIR fluorophores, CRISPR-Cas9-based imaging system, NIR/CRISPR-Cas9-based imaging system
1 Introduction
From Zinc Finger Nucleases (ZFN) to transcription activator-like Effector Nucleases (TALEN), and then to Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system, gene editing technology has been continuously explored and developed (Rui et al., 2019; Li H. et al., 2020; Kwon et al., 2021). Among them, the CRISPR-Cas9 system has become a revolutionary tool in the field of gene editing with its advantages of high efficiency, simple operation, and wide species adaptability (Pickar-Oliver and Gersbach, 2019; Yang et al., 2019). This emerging genome editing system can achieve precise knockout and insertion of specific gene sequences and even the genome of the entire organism, which is also known as “gene scissors” (Jiang and Doudna, 2017).
The development of genome editing allowed the manipulation of any gene in a variety of species and tissues (Hille et al., 2018). However, there was still a lack of accurate understanding of the relationship between operating gene and protein or phenotype. With the increasing interest in noninvasive imaging in vivo, the combination of CRISPR-Cas9 system and optical imaging technology has been studied to a certain extent. A robust CRISPR-Cas9-based imaging system could contribute to us new insights into how the structure and dynamics of molecules influence cell function under normal and abnormal status, which was not easily attainable by current biochemistry-based tools. Therefore, more efforts have been devoted to developing strategies that enable direct visualization of individual molecules by using of CRISPR-Cas9-based imaging system (Fu et al., 2016; Shao et al., 2016; Guo et al., 2019).
In this up-to-date review, we summarized a variety of CRISPR-Cas9 systems that have been developed for imaging of gene loci in living cells, especially in combination with NIR fluorescence (Qin et al., 2017; Li et al., 2019). We expected that with the continuous improvement of CRISPR-Cas9-based imaging technology, important understandings can be obtained to help decipher the function of genes and the mechanisms of diseases.
2 The Mechanism of CRISPR-Cas9 System
The CRISPR-Cas9 system consists of two components: A Cas protein with DNase properties (Cas9) and a single-stranded guide RNA (sgRNA) (Knott and Doudna, 2018; Li L. et al., 2018). Cas9 protein is an RNA-dependent endonuclease containing two nuclease domains, HNH domain and RuvC domain, which are responsible for cutting the complementary and non-complementary strands by pairing sgRNA with the targeting sequence, respectively. (Figures 1A,B) (Jiang and Doudna, 2017). sgRNA is formed by crRNA and tracrRNA (Figure 1C). TracrRNA facilitates the processing of crRNA to mature. The crRNA helps the CRISPR-associated complex to recognize a specific target region of the foreign DNA and guide Cas-proteins to cleave foreign nucleic acid. A 20-base length sequence in the 5′end of sgRNA can be recognized by Cas9 protein and guide to the characteristic target region. PAM (protein assistant motif), a number of nucleotides adjacent to the target site, is a unique and critical component of invading DNA, because CRISPR-Cas needs it to identify and destroy the foreign DNA to produce a double-strand break (DSB). 5′-NGG-3′ as functional PAM can be recognized by Cas9 (Liu et al., 2021). In addition to CRISPR-Cas9, two other Cas proteins have been studied extensively, Cpf1 (also known as Cas12a) and Cas13a. CRISPR-Cpf1 system is more convenient compared with CRISPR-Cas9 system (Zetsche et al., 2015). On one hand, Cpf1 has a lower molecular weight than Cas9, which makes it easier to enter cells and improves the editing rate. On the other hand, Cpf1 only requires crRNA to mediate cleavage, while Cas9 requires the assistance of crRNA and tracrRNA. The major characteristic of Cas13a is that it edits RNAs (Gootenberg et al., 2017). Once Cas13a recognizes and cleaves the target RNA specified by the crRNA, it switches into an enzymatically activated state to bind and cleave any RNAs, regardless of whether they are homologous to crRNA.
The Cas9 induced DSB is repaired under the mechanisms of non-homologous end joining (NHEJ), homology directed repair (HDR) or micro-mediated end joining (MMEJ) (Figure 2) (Zhang et al., 2017). The NHEJ pathway is most commonly used to create deletions and specific gene knock-out (Scully et al., 2019). It directly connects the end of the broken strands (Barman et al., 2020). During the NHEJ process, random insertion, substitution or deletion of bases will occur, which will cause gene mutations (Broeders et al., 2020). NHEJ can also cause frameshifts in the coding sequence of a gene to produce premature truncations, leading to an effective gene knock-out. The HDR pathway requires a homologous DNA sequence (donor DNA) (Nami et al., 2018). Typically, donor DNA for HDR is approximately 750–1,000 kb, which is homologous to that flanking the genomic cleavage site (Petolino, 2015). Homologous recombination is the desired mechanism for precise genome editing, which only happens in the presence of a homologous duplex template (Devkota, 2018). Hence, HDR can achieve precise base insertion or replacement by exogenously introducing homologous templates (Wang et al., 2017). However, the frequency of HDR appears to be extremely low. The MMEJ pathway is a way of DSB repair mediated by micro-homology (MH), which requires micro-homology sequences for repairing comparing with HDR (Bukhari and Muller, 2019). DSB exposed complementary sequences range from 5 to 25 nucleotides (microhomologies) (Seol et al., 2018). These microhomologies are used to align the DNA ends with the occurrence of end bridging. A polymerase then fills in any gaps, ultimately followed by ligation (Zinovkina, 2018). The mutant efficiency of MMEJ is similar to the NHEJ mechanism, which show a high potential for precise gene editing compared with HDR (Seol et al., 2018). Yao and co-workers showed that the mutation frequencies were as high as 20% by using MMEJ-mediated knock-in, which was approximately 10-fold higher than the HDR-based approach (Van Vu et al., 2021).
3 CRISPR-Cas9-Based Imaging System
3.1 Cas9-Based Imaging Systems
Living cell imaging could be achieved by fusing Cas9 with the fluorescent protein (GFP, eGFP or mCherry) to further label and characterize the targeting DNA (Figure 3A) (Chen et al., 2013; Maass et al., 2018). sgRNA-labeled targeting genes could be recognized by the Cas9-GFP to create imaging of living cells (Chen et al., 2018). However, this condition is limited by the high cost of oligo probes. Therefore, it is of great significance to develop a simpler, efficient and robust Cas9-based imaging systems. The CASFISH system, which comprised of dCas9 fused Halo and Halo ligands-conjugated fluorescent dyes, showed remarkably rapid imaging and was applicable for the detection of primary tissue sections (Figure 2A) (Deng et al., 2015). Similarly, the (Po)STAC system utilized scFv-dCas9 fusion protein and GFP-fused scFv antibody to produce fluorescence (Neguembor et al., 2018). By providing the PAM as part of an oligonucleotide (PAMmer), Ning-He Sun et al. (2020) developed a CRISPR-Sunspot system that allows efficient imaging of low-abundance mRNAs. Based on the SunTag system, dCas9 was linked to 24× GCNs, a polypeptide that can recruit specific proteins to achieve signal amplification, could recognized by scFv-GFP proteins, thus the signal was amplified. CRISPR-Sunspot was used to track co-localization of Camk2a mRNA with its regulatory protein Xlr3b in neurons, which provided a novel strategy to unravel the molecular mechanisms of diseases caused by aberrant mRNA molecules. dCas13b-eGFP fused with sgRNA can also be used to track and study the dynamics of nuclear domain-related lncRNAs (Yang et al., 2019).
3.2 sgRNA-Based Imaging Systems
In addition to use dCas9 fused fluorescent proteins, modified sgRNA can also be performed for imaging. A fluorophore-based imaging system consisting of dCas9 and molecular beacon (MB) linked sgRNA had been developed for live-cell visualization (Figure 3B) (Wu et al., 2018). Hong et al. (2018) developed a CRISPR-dCas9 system with bimolecular fluorescence complementation, which used the SunTag system to recruit the N-terminal portion of Venus fluorescent protein and the RNA aptamer (MS2) to recruit the C-terminal portion of Venus fluorescent protein. They were co-transfected with SunTag-dCas9 and MS2-gRNAs for telomere and single genomic locus labeling. Only co-transfection of these two systems could form a complete glowing Venus protein, which solved the false signal interference caused by the accumulation of gRNA. Cell imaging could be achieved by modifying sgRNA with RNA aptamers, which can recruit fluorescent labeled RNA-binding proteins for imaging. The RCasFISH system, which contained sgRNA-linked MS2 and MCP-labeled fluorophores, could be used for in situ quantification of RNA transcriptase in paraffin-embedded tissue (Figure 3B) (Wang et al., 2020). Similarly, this system could perform by lncRNA-protein complex for live cell imaging (Wang et al., 2019; Chen B. et al., 2020). When multiple RNA aptamers fused with different sgRNAs, and different fluorescent labeled RNA-binding protein could be recruited to achieve multicolor imaging (Ma et al., 2016; Wang et al., 2016; Ma et al., 2018; Maass et al., 2018). This method was expected to be a powerful tool for studying the dynamic intrachromosomal and inter-chromosomal interactions during cell cycle progression, while multiple fusion proteins complicate the process of building cell lines.
3.3 Multicolor Imaging Systems Based on Cas9/sgRNA
Multicolor imaging could also be achieved by modifying Cas9 and sgRNA simultaneously (Figure 3C). Halo tag-labeled dCas9 and Cy3-labeled sgRNA complexes bind their target DNA with high affinity, allowing sequential or simultaneous probing of multiple targets and multicolor labeling of target loci in cells (Deng et al., 2015). Currently, the Cas9/sgRNA-based imaging systems have been used to measure the nuclear dynamics and the on-target residence time of dCas9-sgRNA complexes in living cells. Guan et al. (2017) also reported a multiplexed live imaging via CRISPR-Cas9 system. Genomic loci in cells were identified by dCas9-eGFP and modified sgRNA, which could recruit fluorescence-fused RNA-binding proteins. dCas9-eGFP protein and Cy3-labeled sgRNA as fluorescent ribonucleoproteins could visualize the genomic DNA in human bone osteosarcoma cell (Wang et al., 2019).
3.4 Reporter Gene Imaging Systems Driven by CRISPR-Cas9
Reporter genes are widely used to detect the distribution, content, and dynamic activity of proteins in tissues/organs. CRISPR-Cas9 system can be used to generate reporters for living cell imaging and molecular processes (Muntean et al., 2018; Yang et al., 2019; Peng et al., 2020). For example, the luciferase reporter gene was inserted under the promoter by donor DNA and sgRNA, and luciferin was recruited to produce bioluminescence imaging (Figure 3D) (Li Z. et al., 2018). An efficient and scalable system combining CRISPR-Cas9 with fluorescent repressor-operator system, named SHACKTeR, had been reported (Figure 3D). Tet operators (TetO) were inserted as a tag, and eGFP-fused Tet repressors (TetR) were used for visualizing the tag. This system successfully labeled the colon cancer cells (Tasan et al., 2018). Moreover, the combination of PET and CRISPR-Cas9 had been applied in clinical translation of cell-based therapeutics (Ostrominski et al., 2020). HSVtk gene was integrated into the AAVS1 locus of human urinary-induced pluripotent stem cell-derived cardiomyocytes (hUiCMs) using CRISPR-Cas9 system. By combining the probe 18F-FHBG, which could be used for HSVtk tracking, PET imaging provided the insight into the fate of hUiCMs after transplantation (Figure 3D). In another study, PSMA was encoded into human thyroid carcinoma cells by CRISPR-Cas9 and tracked by ACUPA-Cy3-BF3, a small-molecule that delivers positron-emitting fluoride (18F) and a fluorophore (Cy3) to report PSMA expression (Guo et al., 2019). PSMA is an attractive target for the diagnosis and treatment of prostate cancer patients, thus this reporter system showed great potential in PET/fluorescence-guided radical prostatectomy.
4 NIR Imaging and NIR/CRISPR-Cas9-Based Imaging Systems
4.1 NIR Directed Delivery and Activation of CRISPR-Cas9 System
Near-infrared (NIR) fluorescence imaging is mainly based on Near-infrared I (NIR-I, 700–900 nm) and Near-infrared II (NIR-II, 1,000–1,700 nm) (Figure 4) (He et al., 2018). Compared with visible light, biological tissues absorb and scatter less light in the near-infrared band. So NIR fluorescence imaging has significant advantages in providing physiological and pathological information with less damage to biological tissues and less interference to background fluorescence (Li et al., 2020a; Huang and Pu, 2020).
Programmable and inducible genome editing can be manipulated through optical regulation in the NIR window which include photothermal or photosensitive. For photothermal induced CRISPR-Cas9 release, the nanosystem is composed of a photothermal converter and the Cas9 plasmid driven by a heat-inducible promoter. When the plasmid was delivered to the targeted cells, the photothermal converter transform the harvested external light into intracellular local heat. The local heat induced the activation of heat-inducible promoter, thus results in the transcription of Cas9/sgRNA. However, once the light irradiation is switched off, the decreased temperature loss the capacity of intiating the transcription process. For photosensitive induced CRISPR-Cas9 release, the nanosystem can readily undergo photoisomerization or the chemical bond cleavage to release CRISPR-Cas9 when exposed to NIR light.
4.1.1 Delivery and Activation of CRISPR-Cas9 in NIR-I Region
Better tissue differentiation is progressively afforded using fluorescent constructs in the NIR-I spectral region when compared to those emitting in the visible spectral region. The use of NIR-I fluorescent probe can accurately delineate the contour of superficial tumor, and guide the removal of tumor tissue during the operation (Croce and Bottiroli, 2014). However, NIR-I imaging suffers from shallow imaging depth, low contrast, and poor clarity caused by light scattering and autofluorescence. The penetration depth is still not enough for solid tumors due to high tissue scattering.
NIR-I probes have been used for CRISPR-Cas9 delivery and gene therapy. NIR light-triggered thermo-responsive copper sulfide was reported to serve as a “photothermal converter” and stably convert NIR-I light into local thermal effect to release CRISPR-Cas9 (Chen et al., 2021). The codelivery of CRISPR-Cas9 and photosensitizer chlorin e6 (Ce6) can be used in spatial gene editing. Upon NIR irradiation, Ce6 generates reactive oxygen species (ROS), lysosomal escape of nanoparticles was triggered, and Cas9/sgRNA was released in cytoplasm to achieve genome editing (Figure 5A) (Deng et al., 2020). Tao et al. (2021) developed a nanoplatform based on AuNCs, which could deliver Cas9/sgRNA plasmids to cancer cells and released them to achieve efficient genome editing. Peng et al. (2020) reported a NIR-I laser-activated CRISPR-Cas9 nanomachine (LACM). The LACM was irradiated by NIR-I laser to generate heat for sgRNA releasing, which guided the CRISPR-Cas9 genome editing, successfully knocked out the PLK1 gene and induced apoptosis of the target cells (Figure 5B). Combining NIR-I with the photosensitive or light-to-heat conversion elements can spatiotemporally regulate CRISPR-Cas9-based gene editing. Lyu et al. (2019) developed a photolabile semiconducting polymer nanoparticles with NIR-I photoirradiation, which can spontaneously trigger the cleavage of CRISPR-Cas9 by nanoparticles, resulting in the release of CRISPR-Cas9 and subsequent initiation gene editing (Figure 5C). Upconversion nanoparticles which can convert NIR-I light into local ultraviolet light for the cleavage of photosensitive molecules, resulted in on-demand release of CRISPR-Cas9 (Figure 5D). By targeting the tumor gene PLK1, the proliferation of tumor cell can be successfully inhibited via NIR light activated gene editing (Pan et al., 2019). In addition, the combination of CRISPR-Cas9 and upconversion nanoparticles provided the possibility for remote DNA methylation (Chi et al., 2021).
4.1.2 Delivery and Activation of CRISPR-Cas9 in NIR-II Region
Due to the reduction of background autofluorescence from biomolecules, photons at longer wavelengths provide higher contrast between the objects of interest and the background and penetrate deeper into living tissue. Biomedical imaging in NIR-II window can fully improve the temporal and spatial resolution of imaging (about 50 ms and about 25 µm) and penetration depth (up to 10 mm), obtain better image quality and signal-to-background ratio than NIR-I (He et al., 2018). NIR-II fluorescence imaging has been widely used in tumor imaging, liver imaging, small blood vessel imaging, lymph node imaging, and non-invasive dynamic cerebrovascular imaging over the past years (Hong et al., 2014; Zhao et al., 2019; Su et al., 2021). NIR-II imaging can discriminate tumor lesions more effectively than NIR-I imaging and can visualize lesions that are missed in NIR-I imaging (Zhang et al., 2021). A targeted activatable fluorescent nanoprobe in the NIR-II range was reported for in vivo optical dynamic imaging of traumatic brain injury (Li et al., 2020b).
Compared with NIR-I imaging, in vivo NIR-II fluorescence imaging is a relatively newer field of research. Nanomaterials display intrinsic fluorescence emission in the NIR-II window, allowing modulation of emission wavelengths well past the 1,000-nm mark. With the continuous development of chemical synthesis, new fluorophores are constantly discovered, including organic and inorganic fluorescent probes. Organic dyes are the earliest and most researched fluorophores and have been widely used in NIR-II imaging (Li and Pu, 2019; Li et al., 2021). While inorganic fluorescent probes have longer fluorescence lifetime, higher quantum efficiency, and higher fluorescence intensity (He et al., 2019; Nicholas et al., 2019; Yang et al., 2020).
Delivery of CRISPR-Cas9 applying NIR-II fluorophores has been reported. Light-to-heat conversion elements excited by NIR-II can transmit and regulate the release of CRISPR-Cas9. Chen X. et al. (2020) designed a nanosystem (termed nanoCRISPR), which comprised cationic polymer-coated Au nanorod and a heat-inducible Cas9 (Figure 6A). Au nanorod not only serves as a carrier but also can convert photonic energy into local heat to induce the expression of Cas9 endonuclease. Once NIR-II irradiation is switched off, the photothermal effects disappear, causing the inactivation of CRISPR-Cas9 transcription process (Figure 6B). Thus, gene editing can be easily and precisely controlled by fine-tuning the intensity and duration of NIR-II irradiation at multiple time points in vitro and in vivo. The authors also demonstrated that this strategy can be extended to the treatment of deep tumor and fulminant hepatic failure (Figures 6C–I). Tang et al. (2021) also reported a cationic gold nanorod for delivering CRISPR-Cas9 and inducing the expression of Cas9 (Figure 7A). It improved immune checkpoint blockade therapy by CRISPR-Cas9-mediated disruption of PD-L1 and mild-hyperthermia-induced activation of immunogenic cell death. Gold nanorod converts NIR-II light into mild hyperthermia to induce both immunogenic cell death and the expression of Cas9. The genomic disruption of PD-L1 significantly augments immune checkpoint blockade therapy by improving the conversion of dendritic cells to T cells, thereby reprogramming immunosuppressive tumor microenvironment into immunoactive one (Figures 7B–H). The optical regulation of CRISPR-Cas9 by NIR-II light imparts excellent spatial specificity and deep tissue penetration, this strategy therefore can precisely target tumor tissues and circumvent the immune-related adverse events. Moreover, NIR-II spectroscopy was sensitive to changes in chemical bonds of DNA caused by modifying genotype, which has been used in identifying CRISPR-Cas9-based mutants in rice, helping to accelerate the selection and crop breeding process (Feng et al., 2017).
4.2 NIR/CRISPR-Cas9-Based Imaging Systems
In Table 1, we summarize all the NIR fluorophores related to CRISPR-Cas9. Most NIR fluorophores were used for CRISPR-Cas9 delivery, but the NIR/CRISPR-Cas9-based imaging systems have not been widely studied. The NIR fluorescent imaging showed a deep penetration and high resolution in biological tissues, while the Cas9 and sgRNA can be modified to give imaging in vivo. Therefore, the combined application of NIR fluorophores and CRISPR-Cas9 has great innovation and potential in multicolor imaging.
TABLE 1.
NIR-I/II fluorophore | Nanoparticles structures | Excitation (nm) | Emission (nm) | Character | Targets | Application | Ref |
---|---|---|---|---|---|---|---|
SPPF-Dex nps | 808 | 1,000–1,400 | Photothermal conversion, NIR-II imaging, deep tissues | MTH1, HCT 116 cells | CRISPR-Cas9 delivery, real time imaging, animal model | Li et al. (2019) | |
Au nanorod (APC) | 1,064 | 1,000–1,700 | Photothermal activation, deep tissues | AAVS1, asialoglycoprotein receptors targeting, Liver targeting | CRISPR-Cas9 delivery, tumor therapy, animal model | Chen X. et al. (2020) | |
AR@PSS@PCM (ANP) | 1,064 | — | Photothermal activation, deep tissues | PD-L1 targeting, ICD activation | CRISPR-Cas9 delivery, improving immune checkpoint blockade, animal model | Tang et al. (2021) | |
Protamine–AuNCs | 700–1,000 | — | NIR-I imaging, deep tissues | E7, U2OS, HeLa cells | CRISPR-Cas9 delivery, tumor therapy, in vivo | Tao et al. (2021) | |
Photolabile semiconducting polymer nanotransducer | 680/808 | 700–1,000 | Photothermal activation, deep tissues | Plk1, Hela cells | CRISPR-Cas9 delivery, animal model | Lyu et al. (2019) | |
NTA-SS-PEG-PCL/Ce6 Complex | 1,064 | 700–1,000 | Photothermal conversion, deep tissues | Nrf2, CNE-2 cells | CRISPR-Cas9 delivery, tumor therapy, animal model | Deng et al. (2020) | |
UCNPs-Cas9@PEI | 980 | — | Photothermal activation, upconversion, deep tissues | Plk1, kB cells, A549 cells | CRISPR-Cas9 delivery, tumor therapy, animal model | Pan et al. (2019) | |
Upconversion nanoparticles | 700–1,000 | — | Photothermal activation, deep tissues | DNA 5-cytosine methylation, HEK293T cells | CRISPR-Cas9 delivery, animal model | Chi et al. (2021) | |
Gold nanorod (AuNR) | 808 | 700–1,000 | Photothermal therapy, deep tissues | EGFP, EMX1, A549, HEK293T cells | Gene editing, in vivo | Peng et al. (2020) | |
NIR light-triggered thermo-responsive copper sulfide (CuS) | 808 | — | Photothermal therapy, deep tissues | Hsp90α, A375 cells | CRISPR-Cas9 delivery, tumor therapy, animal model | Chen et al. (2021) | |
Si-rhodamine 680SiR | 680 | 700 | NIR-I imaging, deep tissues | SNAP targeting, tubulin2 targeting, U2OS cells | Dual-color confocal and STED imaging, in vivo | Butkevich et al. (2018) |
Butkevich et al. (2018) used CRISPR-Cas9 to generate and detect an endogenous tagged protein by combining with a newly established pair of NIR STED labels (Figure 8A). The synthesis of NIR fluorescent Si-Rhodamine Dye 680SiR was based on 8-Bromojulolidine 1. The 680SiR was expected for SNAP combination, and the other STED dye 610CP could be combined with cytoskeletal protein tubulin2 (Figure 8B). Then the U2OS cell lines expressing SNAP-tagged or Halo-tagged vimentin from its genomic locus were generated by the CRISPR approach. The transgene expression was verified by immunoblotting (Figure 8C). Both the 680SiR-SNAP and the 610CP-tubulin2 demonstrated high brightness and good imaging performance (Figure 8D). The cell-to-cell reproducibility of two-color staining was verified by confocal microscopy. U2OS cells with stable expression of vimentin-SNAP fusion proteins were incubated with 610CP-tubulin2 and 680SiR-SNAP, which showed a superior brightness imaging for clear color separation, and no observable cross-talk between two color channels was detected (Figures 8E,F). In this system, CRISPR-Cas9 offered a robust and reproducible label for NIR imaging in vivo. This approach of endogenous tagging of protein offered reliable and cell-to-cell reproducible dual-color nanoscale imaging in living cells.
NIR fluorophores could not only be used to deliver and control the release of CRISPR-Cas9 through photothermal conversion, but also could be used to monitor the delivery path by NIR imaging. Li et al. (2019) described a type of rationally designed semiconducting polymers (SPs) brush and applied them to NIR-II imaging-guided light-triggered remote control of CRISPR-Cas9 genome editing. SPPF nanoparticles were fabricated by sequentially conjugating alkyl side chains, PEG chains, and fluorinated polyethylenimine (PF) to the backbone of the initial SPs (Figure 9A). The backbone of SPs served as the photothermal transducer, while the PF bound with CRISPR-Cas9 pDNAs via electrostatic interaction and supramolecular interaction. Dexamethasone (Dex) is used for encapsulating in the hydrophobic core of the formed SPPF nanoparticles. Approximately 30% HCT 116-GFP cells showed decreased GFP after SPPF/Cas9-sgGFP incubation upon laser irradiation, and Dex could further enhance the GFP editing efficiency (Figure 9C). The tumor tissue showed bright NIR-II fluorescence signal, suggesting that SPPF could be a good approach to monitor genome editing in vivo. NIR-II fluorescence signal were only observed in metabolically active organs, liver and spleen, indicating the biodegradability of SPPF (Figure 9D). SPPF-Dex/Cas9-sgGFP injection without laser irradiation, PBS or SPPF-Dex/Cas9-sgNull injection with laser irradiation, did not affect the GFP gene disruption (Figure 9E). No abnormal and inflammatory cell infiltration in spleen and liver was observed after treatment, suggesting SPPF exhibited good biocompatibility (Figure 9E). The innovation of this method is to perform visible and controllable in vivo genome editing under near-infrared light guidance and stimulation, which provides a paradigm for tracking the distribution of genome editing system in real time. More studies should be performed to develop this platform in CRISPR-Cas9-based therapeutic approach for genetic disease in the following work. The CRISPR-Cas9-based precise gene therapy and imaging will keep movement clinically in the near future.
5 The Delivery of CRISPR-Cas9-Based Imaging Systems
There are three types of the CRISPR delivery system: 1. delivery the plasmid DNA (pDNA) of Cas9 and sgRNA, 2. deliver the mRNA of Cas9 and sgRNA, 3 deliver the protein (ribonucleoprotein, RNP) of Cas9 and sgRNA, which depend on physical, biological, or chemical manner (Doetschman and Georgieva, 2017; Chen G. et al., 2019; Liu et al., 2019). Physical methods, such as electroporation, are most suitable for in vitro experiments. Viral vectors are commonly used for CRISPR-Cas9 delivery from single cell to in vivo. In clinical trials, more than 70% of gene drug carriers are also viruses (Kim et al., 2017). However, viral vectors may cause unnecessary immunogenicity and mutation risks in the host, thereby limiting their clinical transformation. In terms of biosafety, loading and encapsulation capability, non-viral vectors, especially nanocarriers, have broadened the application in CRISPR-Cas9-based gene therapy (Gu et al., 2018). Several nano-delivery systems for CRISPR-Cas9 have been developed, including cationic liposomes, lipid nanoparticles (LNPs), cationic polymers, vesicles, and gold nanoparticles (Gu et al., 2018). Although nanocarriers offer many advantages for CRISPR-Cas9 delivery in the treatment of cancer and other diseases, some problems remain to be solved. For example, nanoparticles are unstable in blood circulation, the biological distribution of nanoparticles is not ideal, low clearance rate and transfection efficiency, etc. Thus the most of nanocarriers used for CRISPR-Cas9 delivery stay in preclinical studies. More research on reforming nanomaterials of higher biocompatibility, higher efficiency and lower toxicity for loading CRISPR-Cas9 will need be developed. Table 2 shows the characteristic of different CRISPR-Cas9 delivery systems involved in CRISPR-Cas9-based imaging.
TABLE 2.
Delivery vehicle | CRISPR-Cas9 format | Character | Efficiency | Advantage | Disadvantage | Application | Ref |
---|---|---|---|---|---|---|---|
SPPF-Dex nps | Plasmid | Photothermal regulation | 12.8% indel mutation rate in HCT 116-GFP cells | Low toxicity, endolysosomal escape, payloads release | Less loading | In cell, in vivo | Li et al. (2019) |
Au nanorod (APC) | Plasmid | Photothermal regulation | 18.0% indel mutation rate in Hepa1-6 cells, 6.7% indel mutation in the liver tissue | Specific binding | Surface modification is needed to bind genes effectively | In cell, in vivo | Chen X. et al. (2020) |
AR@PSS@PCM(ANP) | Plasmid | Photothermal regulation | 39.7% indel mutation rate in B16F10 cells, 21.5% in tumor | Good biocompatibility, promote intracellular delivery | prone to negatively charge cells and proteins | In cell, in vivo | Tang et al. (2021) |
Protamine–AuNCs | Plasmid | Cationic protamine facilitates release | 27.5% indel mutation rate in HeLa cells | Cell-penetrating properties, nucleus-targeting | Reunion | In cell | Tao et al. (2021) |
Photolabile semiconducting polymer nanotransducer | Plasmid | Photosensitive regulation | Indel 15- and 1.8-fold enhancements in cells and living mice | Efficient release of gene vectors | Low particle surface potential | In cell, in vivo | Lyu et al. (2019) |
NTA-SS-PEG-PCL/Ce6 Complex | Cas9 RNP | Photosensitive regulation | 42.6% indel mutation rate in CNE-2 cells, 31.2% indel mutation rate in tumor | Stability, low toxicity, tumor targeting | Cytotoxicity | In cell, in vivo | Deng et al. (2020) |
UCNPs-Cas9@PEI | Cas9 RNP | Photosensitive regulation | Inhibited cancer cell proliferation and tumor growth | Endosomal escape | Low particle surface potential, less loading | In cell, in vivo | Pan et al. (2019) |
Upconversion nanoparticles | Plasmid | Photosensitive regulation | Inhibited cancer cell proliferation and tumor growth | Light stability, low potential toxicity, no background light interference | Low particle surface potential | In cell, in vivo | Chi et al. (2021) |
Au nanoparticles | Plasmid | Photothermal regulation | 1.24% indel mutation rate inA375 cells, sustainable tumor inhibition | High loading efficiency, good stability, good repetition | Surface modification is needed to bind genes effectively | In cell, in vivo | Wang et al. (2018) |
NIR light-triggered thermo-responsive copper sulfide (CuS) | Cas9 RNP | Photothermal regulation | 37.3%indel mutation rate in A375 cells, 23.8% indel mutationin in tumor | Assist endosomal escape | Reunion, cytotoxicity | In cell, in vivo | Chen et al. (2021) |
Electroporation | RNP, plasmid | Transient transfection, easy to cause damage to cell membranes | High transfection efficiency | Small dependence on cell types, equipment cost | Easy to cause damage to cell membranes | In cell | Chen S. et al. (2019) |
Viral vector (AAV, LV, AdV) | Plasmid | Has been approved for human clinical trials, cause virus contamination | Stable, high transfection efficiency | High capacity | Introduce virus contamination, immune response | In cell, in vivo | Moreno et al. (2020) |
Lipofectamine | RNP, plasmid | Simple preparation, good safety, low cost | High transfection efficiency | Simple preparation, good safety | Prone to immune response | In cell, in vivo | Liu et al. (2020) |
6 Conclusion
The application of the CRISPR-Cas9 system has gradually expanded from genome editing to real-time imaging of living cells. In this review, we described the composition and mechanism of CRISPR-Cas9 system, and summarized the research progress of CRISPR-Cas9-based imaging system in recent research. By modifying Cas9 protein, sgRNA or both with fluorophore, CRISPR-Cas9-based imaging systems achieve multi-color imaging and the combination of PET imaging. We mainly overviewed the NIR imaging and the studies of NIR/CRISPR-Cas9-based imaging systems. We also summarized the application of NIR fluorophores in the delivery of CRISPR-Cas9, which had been widely reported. But there are rarely attempts for combination NIR imaging with CRISPR-Cas9 system. Only two studies have reported NIR/CRISPR-Cas9-based imaging systems, one is for dual-color NIR imaging, and the other is for tracking the location of CRISPR-Cas9 system.
However, there are still some problems need to be solved in this field. Off-target effects have always been a major challenge to limit the application of Cas9 protein, the presence of off-target at high density may lead to false-positive locus detection, thus free fluorescence affects the signal-to-noise ratio and inaccuracy of imaging. More complicated strategies, such as fluorescence resonance energy transfer, can be used to eliminate free luminescence signals (Mao et al., 2019). Improving the FP signal or using a high sensitivity cutting-edge microscope can further optimize the signal-to-noise ratio and improve imaging efficiency (Lu et al., 2021). Delivery is another main challenge in CRISPR-Cas9-based imaging system (Glass et al., 2018; Qiu et al., 2019; Xu et al., 2021). The more efficient, higher compatibility, and lower biotoxicity delivery system will help to realize the clinical potential of this technology. Therefore, designing ideal carrier for targeting tissues of interest is the main task at this stage. It is believed that with the continuous deepening of research, the CRISPR-Cas9 system will be expected to exert its due imaging application value.
In order to successfully translate CRISPR-Cas9-based imaging in clinical applications, it is necessary to continuously perform human and animal experiments. Although many challenges need to be overcome, the potential of CRISPR-Cas9-based imaging will help solve many genome and chromatin mysteries. With the continuous improvement of the CRISPR-Cas9 application, it is expected to become an epoch-making biological technology in other fields.
Author Contributions
HQ, XZ, and DM conceived of the presented idea. HQ, JW, and HW wrote the first draft of the manuscript. XZ and DM wrote sections of the manuscript. HQ, JW, and HW prepared figures. DM, JL and HW contributed to manuscript revision. All authors read, and approved the submitted version.
Funding
This work was supported by the China Postdoctoral Science Foundation of China (no. 2019M661027). The National Natural Science Foundation of China (Grant nos. 91859101).
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
- Anders C., Niewoehner O., Duerst A., Jinek M. (2014). Structural Basis of PAM-Dependent Target DNA Recognition by the Cas9 Endonuclease. Nature 513 (7519), 569–573. 10.1038/nature13579 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Barman A., Deb B., Chakraborty S. (2020). A Glance at Genome Editing with CRISPR-Cas9 Technology. Curr. Genet. 66 (3), 447–462. 10.1007/s00294-019-01040-3 [DOI] [PubMed] [Google Scholar]
- Broeders M., Herrero-Hernandez P., Ernst M. P. T., van der Ploeg A. T., Pijnappel W. W. M. P. (2020). Sharpening the Molecular Scissors: Advances in Gene-Editing Technology. iScience 23 (1), 100789. 10.1016/j.isci.2019.100789 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bukhari H., Müller T. (2019). Endogenous Fluorescence Tagging by CRISPR. Trends Cel Biol. 29 (11), 912–928. 10.1016/j.tcb.2019.08.004 [DOI] [PubMed] [Google Scholar]
- Butkevich A. N., Ta H., Ratz M., Stoldt S., Jakobs S., Belov V. N., et al. (2018). Two-Color 810 Nm STED Nanoscopy of Living Cells with Endogenous SNAP-Tagged Fusion Proteins. ACS Chem. Biol. 13 (2), 475–480. 10.1021/acschembio.7b00616 [DOI] [PubMed] [Google Scholar]
- Chen B., Deng S., Ge T., Ye M., Yu J., Lin S., et al. (2020). Live Cell Imaging and Proteomic Profiling of Endogenous NEAT1 lncRNA by CRISPR/Cas9-mediated Knock-In. Protein Cell 11 (9), 641–660. 10.1007/s13238-020-00706-w [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chen B., Gilbert L. A., Cimini B. A., Schnitzbauer J., Zhang W., Li G.-W., et al. (2013). Dynamic Imaging of Genomic Loci in Living Human Cells by an Optimized CRISPR/Cas System. Cell 155 (7), 1479–1491. 10.1016/j.cell.2013.12.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chen B., Zou W., Xu H., Liang Y., Huang B. (2018). Efficient Labeling and Imaging of Protein-Coding Genes in Living Cells Using CRISPR-Tag. Nat. Commun. 9 (1), 5065. 10.1038/s41467-018-07498-y [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chen C., Ma Y., Du S., Wu Y., Shen P., Yan T., et al. (2021). Controlled CRISPR‐Cas9 Ribonucleoprotein Delivery for Sensitized Photothermal Therapy. Small 17 (33), 2101155. 10.1002/smll.202101155 [DOI] [PubMed] [Google Scholar]
- Chen G., Abdeen A. A., Wang Y., Shahi P. K., Robertson S., Xie R., et al. (2019). A Biodegradable Nanocapsule Delivers a Cas9 Ribonucleoprotein Complex for In Vivo Genome Editing. Nat. Nanotechnol. 14 (10), 974–980. 10.1038/s41565-019-0539-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chen S., Sun S., Moonen D., Lee C., Lee A. Y.-F., Schaffer D. V., et al. (2019). CRISPR-READI: Efficient Generation of Knockin Mice by CRISPR RNP Electroporation and AAV Donor Infection. Cel Rep. 27 (13), 3780–3789. 10.1016/j.celrep.2019.05.103 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chen X., Chen Y., Xin H., Wan T., Ping Y. (2020). Near-infrared Optogenetic Engineering of Photothermal nanoCRISPR for Programmable Genome Editing. Proc. Natl. Acad. Sci. USA 117 (5), 2395–2405. 10.1073/pnas.1912220117 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chi J., Zhao J., Wei S., Li Y., Zhi J., Wang H., et al. (2021). A CRISPR-Cas9-Based Near-Infrared Upconversion-Activated DNA Methylation Editing System. ACS Appl. Mater. Inter. 13 (5), 6043–6052. 10.1021/acsami.0c21223 [DOI] [PubMed] [Google Scholar]
- Croce A. C., Bottiroli G. (2014). Autofluorescence Spectroscopy and Imaging: a Tool for Biomedical Research and Diagnosis. Eur. J. Histochem. 58 (4), 2461. 10.4081/ejh.2014.2461 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Deng W., Shi X., Tjian R., Lionnet T., Singer R. H. (2015). CASFISH: CRISPR/Cas9-mediated In Situ Labeling of Genomic Loci in Fixed Cells. Proc. Natl. Acad. Sci. USA 112 (38), 11870–11875. 10.1073/pnas.1515692112 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Deng S., Li X., Liu S., Chen J., Li M., Chew S. Y., et al. (2020). Codelivery of CRISPR-Cas9 and chlorin e6 for spatially controlled tumor-specific gene editing with synergistic drug effects. Sci. Adv. 6 (29), b4005. 10.1126/sciadv.abb4005 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Devkota S. (2018). The Road Less Traveled: Strategies to Enhance the Frequency of Homology-Directed Repair (HDR) for Increased Efficiency of CRISPR/Cas-mediated Transgenesis. BMB Rep. 51 (9), 437–443. 10.5483/bmbrep.2018.51.9.187 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Doetschman T., Georgieva T. (2017). Gene Editing with CRISPR/Cas9 RNA-Directed Nuclease. Circ. Res. 120 (5), 876–894. 10.1161/CIRCRESAHA.116.309727 [DOI] [PubMed] [Google Scholar]
- Feng X., Peng C., Chen Y., Liu X., Feng X., He Y. (2017). Discrimination of CRISPR/Cas9-induced Mutants of Rice Seeds Using Near-Infrared Hyperspectral Imaging. Sci. Rep. 7 (1), 15934. 10.1038/s41598-017-16254-z [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fu Y., Rocha P. P., Luo V. M., Raviram R., Deng Y., Mazzoni E. O., et al. (2016). CRISPR-dCas9 and sgRNA Scaffolds Enable Dual-Colour Live Imaging of Satellite Sequences and Repeat-Enriched Individual Loci. Nat. Commun. 7, 11707. 10.1038/ncomms11707 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Glass Z., Lee M., Li Y., Xu Q. (2018). Engineering the Delivery System for CRISPR-Based Genome Editing. Trends Biotechnol. 36 (2), 173–185. 10.1016/j.tibtech.2017.11.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gootenberg J. S., Abudayyeh O. O., Lee J. W., Essletzbichler P., Dy A. J., Joung J., et al. (2017). Nucleic Acid Detection with CRISPR-Cas13a/C2c2. Science 356 (6336), 438–442. 10.1126/science.aam9321 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gu B., Posfai E., Rossant J. (2018). Efficient Generation of Targeted Large Insertions by Microinjection into Two-Cell-Stage Mouse Embryos. Nat. Biotechnol. 36 (7), 632–637. 10.1038/nbt.4166 [DOI] [PubMed] [Google Scholar]
- Guan J., Liu H., Shi X., Feng S., Huang B. (2017). Tracking Multiple Genomic Elements Using Correlative CRISPR Imaging and Sequential DNA FISH. Biophys. J. 112 (6), 1077–1084. 10.1016/j.bpj.2017.01.032 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Guo H., Kommidi H., Vedvyas Y., McCloskey J. E., Zhang W., Chen N., et al. (2019). A Fluorescent, [18F]-Positron-Emitting Agent for Imaging Prostate-specific Membrane Antigen Allows Genetic Reporting in Adoptively Transferred, Genetically Modified Cells. ACS Chem. Biol. 14 (7), 1449–1459. 10.1021/acschembio.9b00160 [DOI] [PMC free article] [PubMed] [Google Scholar]
- He S., Song J., Qu J., Cheng Z. (2018). Crucial Breakthrough of Second Near-Infrared Biological Window Fluorophores: Design and Synthesis toward Multimodal Imaging and Theranostics. Chem. Soc. Rev. 47 (12), 4258–4278. 10.1039/c8cs00234g [DOI] [PubMed] [Google Scholar]
- He S., Chen S., Li D., Wu Y., Zhang X., Liu J., et al. (2019). High Affinity to Skeleton Rare Earth Doped Nanoparticles for Near-Infrared II Imaging. Nano Lett. 19 (5), 2985–2992. 10.1021/acs.nanolett.9b00140 [DOI] [PubMed] [Google Scholar]
- Hille F., Richter H., Wong S. P., Bratovič M., Ressel S., Charpentier E. (2018). The Biology of CRISPR-Cas: Backward and Forward. Cell 172 (6), 1239–1259. 10.1016/j.cell.2017.11.032 [DOI] [PubMed] [Google Scholar]
- Hong G., Lee J. C., Jha A., Diao S., Nakayama K. H., Hou L., et al. (2014). Near-infrared II Fluorescence for Imaging Hindlimb Vessel Regeneration with Dynamic Tissue Perfusion Measurement. Circ. Cardiovasc. Imaging 7 (3), 517–525. 10.1161/CIRCIMAGING.113.000305 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hong Y., Lu G., Duan J., Liu W., Zhang Y. (2018). Comparison and Optimization of CRISPR/dCas9/gRNA Genome-Labeling Systems for Live Cell Imaging. Genome Biol. 19 (1), 39. 10.1186/s13059-018-1413-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Huang J., Pu K. (2020). Activatable Molecular Probes for Second Near‐Infrared Fluorescence, Chemiluminescence, and Photoacoustic Imaging. Angew. Chem. Int. Ed. 59 (29), 11717–11731. 10.1002/anie.202001783 [DOI] [PubMed] [Google Scholar]
- Jiang F., Doudna J. A. (2017). CRISPR-Cas9 Structures and Mechanisms. Annu. Rev. Biophys. 46, 505–529. 10.1146/annurev-biophys-062215-010822 [DOI] [PubMed] [Google Scholar]
- Kim K., Ryu S.-M., Kim S.-T., Baek G., Kim D., Lim K., et al. (2017). Highly Efficient RNA-Guided Base Editing in Mouse Embryos. Nat. Biotechnol. 35 (5), 435–437. 10.1038/nbt.3816 [DOI] [PubMed] [Google Scholar]
- Knott G. J., Doudna J. A. (2018). CRISPR-cas Guides the Future of Genetic Engineering. Science 361 (6405), 866–869. 10.1126/science.aat5011 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kwon Y.-W., Ahn H.-S., Lee J.-W., Yang H.-M., Cho H.-J., Kim S. J., et al. (2021). HLA DR Genome Editing with TALENs in Human iPSCs Produced Immune-Tolerant Dendritic Cells. Stem Cell Int. 2021, 8873383. 10.1155/2021/8873383 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Li J., Pu K. (2019). Development of Organic Semiconducting Materials for Deep-Tissue Optical Imaging, Phototherapy and Photoactivation. Chem. Soc. Rev. 48 (1), 38–71. 10.1039/c8cs00001h [DOI] [PubMed] [Google Scholar]
- Li L., Yang Z., Zhu S., He L., Fan W., Tang W., et al. (2019). A Rationally Designed Semiconducting Polymer Brush for NIR‐II Imaging‐Guided Light‐Triggered Remote Control of CRISPR/Cas9 Genome Editing. Adv. Mater. 31 (21), 1901187. 10.1002/adma.201901187 [DOI] [PubMed] [Google Scholar]
- Li C., Chen G., Zhang Y., Wu F., Wang Q. (2020a). Advanced Fluorescence Imaging Technology in the Near-Infrared-II Window for Biomedical Applications. J. Am. Chem. Soc. 142 (35), 14789–14804. 10.1021/jacs.0c07022 [DOI] [PubMed] [Google Scholar]
- Li C., Li W., Liu H., Zhang Y., Chen G., Li Z., et al. (2020b). An Activatable NIR‐II Nanoprobe for In Vivo Early Real‐Time Diagnosis of Traumatic Brain Injury. Angew. Chem. Int. Ed. 59 (1), 247–252. 10.1002/anie.201911803 [DOI] [PubMed] [Google Scholar]
- Li X., Liang X., Yin J., Lin W. (2021). Organic Fluorescent Probes for Monitoring Autophagy in Living Cells. Chem. Soc. Rev. 50 (1), 102–119. 10.1039/d0cs00896f [DOI] [PubMed] [Google Scholar]
- Li H., Yang Y., Hong W., Huang M., Wu M., Zhao X. (2020). Applications of Genome Editing Technology in the Targeted Therapy of Human Diseases: Mechanisms, Advances and Prospects. Sig Transduct. Target. Ther. 5 (1), 1. 10.1038/s41392-019-0089-y [DOI] [PMC free article] [PubMed] [Google Scholar]
- Li L., Hu S., Chen X. (2018). Non-viral Delivery Systems for CRISPR/Cas9-based Genome Editing: Challenges and Opportunities. Biomaterials 171, 207–218. 10.1016/j.biomaterials.2018.04.031 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Li Z., Zhao J., Muhammad N., Wang D., Mao Q., Xia H. (2018). Establishment of a HEK293 Cell Line by CRISPR/Cas9-mediated Luciferase Knock-In to Study Transcriptional Regulation of the Human SREBP1 Gene. Biotechnol. Lett. 40 (11-12), 1495–1506. 10.1007/s10529-018-2608-2 [DOI] [PubMed] [Google Scholar]
- Liu J., Chang J., Jiang Y., Meng X., Sun T., Mao L., et al. (2019). Fast and Efficient CRISPR/Cas9 Genome Editing In Vivo Enabled by Bioreducible Lipid and Messenger RNA Nanoparticles. Adv. Mater. 31 (33), 1902575. 10.1002/adma.201902575 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Liu W., Rudis M. R., Cheplick M. H., Millwood R. J., Yang J.-P., Ondzighi-Assoume C. A., et al. (2020). Lipofection-mediated Genome Editing Using DNA-free Delivery of the Cas9/gRNA Ribonucleoprotein into Plant Cells. Plant Cel Rep. 39 (2), 245–257. 10.1007/s00299-019-02488-w [DOI] [PubMed] [Google Scholar]
- Liu Z., Chen S., Jia Y., Shan H., Chen M., Song Y., et al. (2021). Efficient and High-Fidelity Base Editor with Expanded PAM Compatibility for Cytidine Dinucleotide. Sci. China Life Sci. 64, 1355–1367. 10.1007/s11427-020-1775-2 [DOI] [PubMed] [Google Scholar]
- Lu S., Wang D., Hou Y., Guo D., Deng Y., Zhang X.-E. (2021). Illuminating Single Genomic Loci in Live Cells by Reducing Nuclear Background Fluorescence. Sci. China Life Sci. 64 (5), 667–677. 10.1007/s11427-020-1794-2 [DOI] [PubMed] [Google Scholar]
- Lyu Y., He S., Li J., Jiang Y., Sun H., Miao Y., et al. (2019). A Photolabile Semiconducting Polymer Nanotransducer for Near‐Infrared Regulation of CRISPR/Cas9 Gene Editing. Angew. Chem. Int. Ed. 58 (50), 18197–18201. 10.1002/anie.201909264 [DOI] [PubMed] [Google Scholar]
- Ma H., Tu L.-C., Naseri A., Huisman M., Zhang S., Grunwald D., et al. (2016). Multiplexed Labeling of Genomic Loci with dCas9 and Engineered sgRNAs Using CRISPRainbow. Nat. Biotechnol. 34 (5), 528–530. 10.1038/nbt.3526 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ma H., Tu L.-C., Naseri A., Chung Y.-C., Grunwald D., Zhang S., et al. (2018). CRISPR-sirius: RNA Scaffolds for Signal Amplification in Genome Imaging. Nat. Methods 15 (11), 928–931. 10.1038/s41592-018-0174-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Maass P. G., Barutcu A. R., Shechner D. M., Weiner C. L., Melé M., Rinn J. L. (2018). Spatiotemporal Allele Organization by Allele-specific CRISPR Live-Cell Imaging (SNP-CLING). Nat. Struct. Mol. Biol. 25 (2), 176–184. 10.1038/s41594-017-0015-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mao S., Ying Y., Wu X., Krueger C. J., Chen A. K. (2019). CRISPR/dual-FRET Molecular beacon for Sensitive Live-Cell Imaging of Non-repetitive Genomic Loci. Nucleic Acids Res. 47 (20), e131. 10.1093/nar/gkz752 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Moreno A. M., Fu X., Zhu J., Katrekar D., Shih Y.-R. V., Marlett J., et al. (2020). In Situ Gene Therapy via AAV-CRISPR-Cas9-Mediated Targeted Gene Regulation. Mol. Ther. 28 (8), 1931. 10.1016/j.ymthe.2020.06.027 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Muntean B. S., Zucca S., MacMullen C. M., Dao M. T., Johnston C., Iwamoto H., et al. (2018). Interrogating the Spatiotemporal Landscape of Neuromodulatory GPCR Signaling by Real-Time Imaging of cAMP in Intact Neurons and Circuits. Cel Rep. 22 (1), 255–268. 10.1016/j.celrep.2017.12.022 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nami F., Basiri M., Satarian L., Curtiss C., Baharvand H., Verfaillie C. (2018). Strategies for In Vivo Genome Editing in Nondividing Cells. Trends Biotechnol. 36 (8), 770–786. 10.1016/j.tibtech.2018.03.004 [DOI] [PubMed] [Google Scholar]
- Neguembor M. V., Sebastian-Perez R., Aulicino F., Gomez-Garcia P. A., Cosma M. P., Lakadamyali M. (2018). (Po)STAC (Polycistronic SunTAg Modified CRISPR) Enables Live-Cell and Fixed-Cell Super-resolution Imaging of Multiple Genes. Nucleic Acids Res. 46 (5), e30. 10.1093/nar/gkx1271 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nicholas J., Chen H., Liu K., Venu I., Bolser D., Saleh N. B., et al. (2019). Utilization of Near Infrared Fluorescence Imaging to Track and Quantify the Pulmonary Retention of Single-Walled Carbon Nanotubes in Mice. NanoImpact 14, 100167. 10.1016/j.impact.2019.100167 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ostrominski J. W., Yada R. C., Sato N., Klein M., Blinova K., Patel D., et al. (2020). CRISPR/Cas9‐mediated Introduction of the Sodium/iodide Symporter Gene Enables Noninvasive In Vivo Tracking of Induced Pluripotent Stem Cell‐Derived Cardiomyocytes. Stem Cell Transl. Med. 9 (10), 1203–1217. 10.1002/sctm.20-0019 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pan Y., Yang J., Luan X., Liu X., Li X., Yang J., et al. (2019). Near-infrared Upconversion-Activated CRISPR-Cas9 System: A Remote-Controlled Gene Editing Platform. Sci. Adv. 5 (4), v7199. 10.1126/sciadv.aav7199 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Peng H., Le C., Wu J., Li X.-F., Zhang H., Le X. C. (2020). A Genome-Editing Nanomachine Constructed with a Clustered Regularly Interspaced Short Palindromic Repeats System and Activated by Near-Infrared Illumination. ACS Nano 14 (3), 2817–2826. 10.1021/acsnano.9b05276 [DOI] [PubMed] [Google Scholar]
- Petolino J. F. (2015). Genome Editing in Plants via Designed Zinc finger Nucleases. In Vitro Cell.Dev.Biol.-Plant 51 (1), 1–8. 10.1007/s11627-015-9663-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pickar-Oliver A., Gersbach C. A. (2019). The Next Generation of CRISPR-Cas Technologies and Applications. Nat. Rev. Mol. Cel Biol. 20 (8), 490–507. 10.1038/s41580-019-0131-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Qin P., Parlak M., Kuscu C., Bandaria J., Mir M., Szlachta K., et al. (2017). Live Cell Imaging of Low- and Non-repetitive Chromosome Loci Using CRISPR-Cas9. Nat. Commun. 8, 14725. 10.1038/ncomms14725 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Qiu M., Glass Z., Xu Q. (2019). Nonviral Nanoparticles for CRISPR-Based Genome Editing: Is it Just a Simple Adaption of what Have Been Developed for Nucleic Acid Delivery? Biomacromolecules 20 (9), 3333–3339. 10.1021/acs.biomac.9b00783 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rui Y., Wilson D. R., Green J. J. (2019). Non-Viral Delivery to Enable Genome Editing. Trends Biotechnol. 37 (3), 281–293. 10.1016/j.tibtech.2018.08.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Scully R., Panday A., Elango R., Willis N. A. (2019). DNA Double-Strand Break Repair-Pathway Choice in Somatic Mammalian Cells. Nat. Rev. Mol. Cel. Biol. 20 (11), 698–714. 10.1038/s41580-019-0152-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Seol J.-H., Shim E. Y., Lee S. E. (2018). Microhomology-mediated End Joining: Good, Bad and Ugly. Mutat. Res./Fundam. Mol. Mech. Mutagen. 809, 81–87. 10.1016/j.mrfmmm.2017.07.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Shao S., Zhang W., Hu H., Xue B., Qin J., Sun C., et al. (2016). Long-Term Dual-Color Tracking of Genomic Loci by Modified sgRNAs of the CRISPR/Cas9 System. Nucleic Acids Res. 44 (9), e86. 10.1093/nar/gkw066 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Su Y., Yu B., Wang S., Cong H., Shen Y. (2021). NIR-II Bioimaging of Small Organic Molecule. Biomaterials 271, 120717. 10.1016/j.biomaterials.2021.120717 [DOI] [PubMed] [Google Scholar]
- Sun N.-H., Chen D.-Y., Ye L.-P., Sheng G., Gong J.-J., Chen B.-H., et al. (2020). CRISPR-Sunspot: Imaging of Endogenous Low-Abundance RNA at the Single-Molecule Level in Live Cells. Theranostics 10 (24), 10993–11012. 10.7150/thno.43094 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tang H., Xu X., Chen Y., Xin H., Wan T., Li B., et al. (2021). Reprogramming the Tumor Microenvironment through Second‐Near‐Infrared‐Window Photothermal Genome Editing of PD‐L1 Mediated by Supramolecular Gold Nanorods for Enhanced Cancer Immunotherapy. Adv. Mater. 33 (12), 2006003. 10.1002/adma.202006003 [DOI] [PubMed] [Google Scholar]
- Tao Y., Yi K., Hu H., Shao D., Li M. (2021). Coassembly of Nucleus-Targeting Gold Nanoclusters with CRISPR/Cas9 for Simultaneous Bioimaging and Therapeutic Genome Editing. J. Mater. Chem. B 9 (1), 94–100. 10.1039/d0tb01925a [DOI] [PubMed] [Google Scholar]
- Tasan I., Sustackova G., Zhang L., Kim J., Sivaguru M., HamediRad M., et al. (2018). CRISPR/Cas9-mediated Knock-In of an Optimized TetO Repeat for Live Cell Imaging of Endogenous Loci. Nucleic Acids Res. 46 (17), e100. 10.1093/nar/gky501 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Vu T., Doan D., Kim J., Sung Y. W., Tran M., Song Y. J., et al. (2021). CRISPR/Cas‐based Precision Genome Editing via Microhomology‐mediated End Joining. Plant Biotechnol. J. 19 (2), 230–239. 10.1111/pbi.13490 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wang S., Su J.-H., Zhang F., Zhuang X. (2016). An RNA-Aptamer-Based Two-Color CRISPR Labeling System. Sci. Rep. 6, 26857. 10.1038/srep26857 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wang H.-X., Li M., Lee C. M., Chakraborty S., Kim H.-W., Bao G., et al. (2017). CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery. Chem. Rev. 117 (15), 9874–9906. 10.1021/acs.chemrev.6b00799 [DOI] [PubMed] [Google Scholar]
- Wang P., Zhang L., Zheng W., Cong L., Guo Z., Xie Y., et al. (2018). Thermo-triggered Release of CRISPR-Cas9 System by Lipid-Encapsulated Gold Nanoparticles for Tumor Therapy. Angew. Chem. Int. Ed. 57 (6), 1491–1496. 10.1002/anie.201708689 [DOI] [PubMed] [Google Scholar]
- Wang H., Nakamura M., Abbott T. R., Zhao D., Luo K., Yu C., et al. (2019). CRISPR-mediated Live Imaging of Genome Editing and Transcription. Science 365 (6459), 1301–1305. 10.1126/science.aax7852 [DOI] [PubMed] [Google Scholar]
- Wang M., Chen K., Wu Q., Peng R., Zhang R., Li J. (2020). RCasFISH: CRISPR/dCas9-Mediated In Situ Imaging of mRNA Transcripts in Fixed Cells and Tissues. Anal. Chem. 92 (3), 2468–2475. 10.1021/acs.analchem.9b03797 [DOI] [PubMed] [Google Scholar]
- Wu X., Mao S., Yang Y., Rushdi M. N., Krueger C. J., Chen A. K. (2018). A CRISPR/molecular beacon Hybrid System for Live-Cell Genomic Imaging. Nucleic Acids Res. 46 (13), e80. 10.1093/nar/gky304 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Xu C. F., Chen G. J., Luo Y. L., Zhang Y., Zhao G., Lu Z. D., et al. (2021). Rational Designs of in vivo CRISPR-Cas Delivery Systems. Adv. Drug Deliv. Rev. 168, 3–29. 10.1016/j.addr.2019.11.005 [DOI] [PubMed] [Google Scholar]
- Yang L.-Z., Wang Y., Li S.-Q., Yao R.-W., Luan P.-F., Wu H., et al. (2019). Dynamic Imaging of RNA in Living Cells by CRISPR-Cas13 Systems. Mol. Cel. 76 (6), 981–997. 10.1016/j.molcel.2019.10.024 [DOI] [PubMed] [Google Scholar]
- Yang Y., Yu Y., Chen H., Meng X., Ma W., Yu M., et al. (2020). Illuminating Platinum Transportation while Maximizing Therapeutic Efficacy by Gold Nanoclusters via Simultaneous Near-Infrared-I/II Imaging and Glutathione Scavenging. ACS Nano 14 (10), 13536–13547. 10.1021/acsnano.0c05541 [DOI] [PubMed] [Google Scholar]
- Zetsche B., Gootenberg J. S., Abudayyeh O. O., Slaymaker I. M., Makarova K. S., Essletzbichler P., et al. (2015). Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System. Cell 163 (3), 759–771. 10.1016/j.cell.2015.09.038 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zhang J.-P., Li X.-L., Li G.-H., Chen W., Arakaki C., Botimer G. D., et al. (2017). Efficient Precise Knockin with a Double Cut HDR Donor after CRISPR/Cas9-Mediated Double-Stranded DNA Cleavage. Genome Biol. 18 (1), 35. 10.1186/s13059-017-1164-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zhang X., Wang W., Su L., Ge X., Ye J., Zhao C., et al. (2021). Plasmonic-Fluorescent Janus Ag/Ag2S Nanoparticles for In Situ H2O2-Activated NIR-II Fluorescence Imaging. Nano Lett. 21 (6), 2625–2633. 10.1021/acs.nanolett.1c00197 [DOI] [PubMed] [Google Scholar]
- Zhao M., Li B., Fan Y., Zhang F. (2019). In Vivo Assembly and Disassembly of Probes to Improve Near‐Infrared Optical Bioimaging. Adv. Healthc. Mater. 8 (13), 1801650. 10.1002/adhm.201801650 [DOI] [PubMed] [Google Scholar]
- Zinovkina L. A. (2018). Mechanisms of Mitochondrial DNA Repair in Mammals. Biochem. Mosc. 83 (3), 233–249. 10.1134/S0006297918030045 [DOI] [PubMed] [Google Scholar]